Suchergebnisse - (Subject:"O3J8G9O825")

PubPharm (1.712)

71

Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

enthalten in: HIV research & clinical practice | 2021

von Monin, M. | Kümmerle, T. | Schneider, J. | +16

72

Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs : A Case Study of Lopinavir/Ritonavir

enthalten in: Journal of pharmaceutical sciences | 2021

von Saeed, A. | Schmidt, J. | Munasinghe, W. | +4

73

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

enthalten in: Trials | 2021

von Walimbwa, S. | Kaboggoza, J. | Waitt, C. | +3

74

Lopinavir and tenofovir interaction observed in non-pregnant adults altered during pregnancy

enthalten in: Journal of clinical pharmacy and therapeutics | 2021

von Mulligan, N. | Salama, E. | Momper, J. | +6

75

Brief Report : Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2021

von Chawana, T. | Nhachi, C. | Nathoo, K. | +8

76

Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19 : a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data

enthalten in: International journal of clinical pharmacy | 2021

von Tang, H. | Zhou, L. | Li, X. | +5

77

Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Kendall, M. | Lalloo, U. | Fletcher, C. | +5

78

Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda

enthalten in: BMC infectious diseases | 2021

von Mulindwa, F. | Castelnuovo, B. | Kirenga, B. | +4

79

Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age

enthalten in: AIDS (London, England) | 2021

von MacBrayne, C. | Rutstein, R. | Wiznia, A. | +17

CommentIn: AIDS. 2021 Jul 15;35(9):1497-1498. - PMID 34185714

80

Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings

enthalten in: AIDS (London, England) | 2021

von Apornpong, T. | Grinsztejn, B. | Hughes, M. | +23